• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Novo Nordisk (CPSE:NOVO B) Could Be 69% Undervalued Following Buyback And Semaglutide Filings

    Simply Wall St·10/16/2026 00:36:12
    语音播报

    Novo Nordisk (CPSE:NOVO B) is back in focus after a series of fresh developments, including a large share repurchase plan, new semaglutide filings, and a biologics licensing deal with Ablexis that together reshape the long term story.

    The recent announcements around denecimig, new semaglutide filings, and the Ablexis license arrive at a time when Novo Nordisk's share price has been under pressure. The stock is down 20.1% on a 90 day share price return and the 1 year total shareholder return has declined 24.6%. At the same time, short term momentum has picked up, with a 1 day share price return of 2.9% and a 7 day share price return of 5.4%. This suggests investors are reassessing the risk and opportunity in light of the buyback program and pipeline progress.

    Spot potential rebound stories alongside Novo Nordisk by scanning our handpicked 197 high quality undervalued stocks that the market may be pricing too cautiously right now.

    After a drop that leaves Novo Nordisk trading below many analyst targets and some fair value estimates, the buyback, denecimig delay and semaglutide filings pull in opposite directions. Is that discount a sign of caution or an opportunity?

    Most Popular Narrative: 69% Undervalued

    Narrative followers currently see a large gap between Novo Nordisk's last close at DKK263.45 and a fair value estimate of DKK851.04. They frame the recent share price slide as a valuation reset rather than a structural break.

    The recent drop in the share price is, in my view, largely a correction of previous market overexuberance, not a reflection of structural issues. Novo is neither a weak company nor in trouble. While many are currently pulling back, I am personally using this opportunity to add to my position.

    See why 93 investors see Novo Nordisk as 69% undervalued.

    Result: Fair Value of DKK851.04 (UNDERVALUED)

    Still, this upbeat Novo Nordisk story can unravel quickly if GLP-1 price pressure intensifies further, or if capacity expansions and new product rollouts slip.

    Find out about the key risks to this Novo Nordisk narrative.

    Next Steps

    Mixed messages on Novo Nordisk's outlook can pull you in either direction, so move quickly, review the evidence, and weigh up its 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Novo Nordisk?

    If you only focus on Novo Nordisk, you may miss other opportunities that fit your risk level and income goals just as well.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.